Clinical trial
A Three-Part, Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-HBVS in Healthy Volunteers and Patients With Chronic Hepatitis B
NCT03772249 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Three-Part, Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-HBVS in Healthy Volunteers and Patients With Chronic Hepatitis B
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 28, 2018
- Completion date
- July 12, 2022
- Enrollment
- 82 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.